See the DrugPatentWatch profile for Zinbryta
What patent protects Zinbryta (daclizumab) at the “composition of matter” level?
Zinbryta is daclizumab, and a “composition of matter” patent typically means protection on the drug substance itself (the active ingredient’s chemical/formulation composition), not just how it’s used. However, the specific U.S. “composition of matter” patent number(s) for Zinbryta are not provided in the information available here, so I can’t accurately name the exact patent(s) without a source to cite.
Which U.S. patents are commonly tied to biologics like daclizumab?
For biologics, U.S. protection often comes in layers:
- “Composition of matter” for the active biologic (or its defined composition/structure)
- Method-of-treatment patents (how to use it for specific indications)
- Formulation or manufacturing-process patents (how it’s made or presented)
To identify the exact “composition of matter” patent for Zinbryta in the U.S., you’d usually check:
- The FDA’s biologics license application (BLA) records and related patent listings (the “Orange Book” for biologics is the publication where patent listings show up)
- The patent family/assignments tied to daclizumab and the brand “Zinbryta” in USPTO records
How can you find the exact U.S. “composition of matter” patent number quickly?
If you want, share one of the following and I can map it to the correct U.S. “composition of matter” patent(s):
- the FDA BLA number for Zinbryta (or a link to the FDA page you’re looking at)
- the patent listing text you have (even a partial snippet)
- any USPTO publication number you’ve seen for daclizumab/Zinbryta
With that, I can identify which of the listed patents is specifically described as a composition-of-matter patent and give the correct U.S. patent number(s).
Why the exact answer matters (and what can trip people up)
People often search “composition of matter” for biologics but then run into:
- patents that are actually method-of-use, not composition-of-matter
- patents in the same family that cover different jurisdictions (US vs EP/WO)
- multiple patents covering different claim categories (active, formulation, manufacturing)
So the key is matching the claim type shown in the patent record (and/or the FDA patent listing category) to the “composition of matter” label.
If you paste the Zinbryta FDA patent listing entry you’re looking at (or the BLA number), I’ll return the exact U.S. “composition of matter” patent number(s).